Our blog

Your Body Makes Its Own GLP-1. Why Doesn't It Last?

Reading time
5 min read
Topic
Longevity
Published

Native GLP-1 signals for only one to two minutes before an enzyme breaks it down — exactly the problem GLP-1 medications are chemically engineered to outlast.

Every time you eat, cells lining your gut release a hormone called GLP-1, which tells your pancreas to release insulin and your stomach to slow down. Within about one to two minutes, an enzyme called DPP-4 cuts it apart — and that built-in shutoff is exactly what GLP-1 medications are chemically engineered to outlast.

In brief:

  • Native GLP-1 is degraded by the enzyme DPP-4 within roughly one to two minutes of release, so its signal fades almost as fast as it starts.
  • GLP-1 medications work because they're modified to resist that same enzyme, letting the signal last for hours or days instead of minutes.
  • A longer-acting signal is a manufacturing choice, not evidence that the medication is "more" of the hormone — it's the same molecule, built to survive.

What does GLP-1 actually do in the body?

GLP-1 is made by enteroendocrine cells in your small intestine and released within minutes of eating. Once in circulation, it travels to several targets at once: it tells the pancreas to release insulin only when blood sugar is actually elevated, it suppresses the release of glucagon (a hormone that raises blood sugar), it slows the rate food leaves your stomach, and it acts on appetite circuits to reduce food intake. Researchers describe these as the hormone's "incretin" effects — the signals that help your body handle a meal once it arrives.

Why does the signal disappear so fast?

Because an enzyme is built to destroy it almost immediately. DPP-4 (dipeptidyl peptidase-4) clips a specific point near the front of the GLP-1 molecule, and it does this so efficiently that native GLP-1's plasma half-life is only about one to two minutes. That means most of the hormone your gut releases after a meal never survives long enough to reach every target it could otherwise affect — it's less a steady broadcast than a rapid pulse that's gone almost as soon as it starts.

How do GLP-1 medications get around that?

By changing the molecule enough that DPP-4 can no longer cut it apart efficiently, while leaving the part that activates the GLP-1 receptor intact. That single engineering change is what separates a medication from the hormone it's modeled on: instead of lasting a minute or two, a modified GLP-1 receptor agonist can keep signaling for hours (a daily formulation) or days (a weekly formulation), which is also why these medications come in both short- and long-acting versions rather than one standard dose. The dosing interval printed on the label is a direct readout of how thoroughly that particular molecule resists degradation — not a measure of how strong or effective it is.

What the research says

Drucker's 2018 review in Cell Metabolism lays out the distinction this article turns on: the circuits activated by the GLP-1 your gut makes are not identical to the circuits engaged by a pharmacological GLP-1 receptor agonist, precisely because the two are handled so differently once they're in the body.¹ Fineman and colleagues, reviewing GLP-1-based therapies in Diabetes, Obesity and Metabolism, state the mechanism in concrete terms: native GLP-1 has "significant limitations as a therapeutic due to its rapid degradation (plasma half-life of 1-2 min) by dipeptidyl peptidase-4," which is why two classes of medication now exist — drugs that block DPP-4 itself, and DPP-4-resistant GLP-1 receptor agonists, the latter further divided into short- and long-acting forms.²

Both sources are pharmacology reviews that synthesize decades of prior research rather than new clinical trials, so they describe mechanism and consensus understanding, not a single study's outcome in a specific population. Neither source compares one medication's effectiveness to another's, and neither suggests that a longer-acting formulation produces a better result for an individual patient — only that it changes how often the drug needs to be taken.

What you can do this week

  • Ask your clinician why your medication's dosing interval is what it is. A molecule's resistance to DPP-4 is what decides whether it's a daily pill or a weekly injection — not how "strong" it is.
  • Don't expect a dose to feel like it "kicks in and fades" the way a cup of coffee might. Unlike the minutes-long pulses of native GLP-1, a modified GLP-1 receptor agonist maintains a steadier level between doses, which is part of why timing a dose around one specific meal doesn't matter the way it would for the hormone your gut makes on its own.
  • If you're weighing whether a GLP-1 medication is right for you, that's a conversation for a clinician, not a guess from a dosing chart. Pallas prescribes GLP-1 medications — compounded and FDA-approved — when a US-licensed clinician decides it's appropriate.

Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.

Your body isn't failing when its own GLP-1 fades in a couple of minutes — that's simply how the hormone is designed to work, as a quick pulse tied to each meal. The medications built on it exist because chemists found a way to keep that same signal switched on far longer than biology ever intended it to run.

Google highlights your preferred sources.

Add Pallas as a preferred source

Frequently asked questions

Because an enzyme called DPP-4 breaks it down within about one to two minutes of release, according to published reviews of GLP-1 pharmacology. GLP-1 medications work because they're chemically modified to resist that same enzyme, letting the signal last for hours or days instead of minutes.

The GLP-1 your gut makes naturally has a plasma half-life of only about one to two minutes before DPP-4 degrades it. A modified GLP-1 receptor agonist used as a medication is built to resist that same enzyme, so it can remain active for far longer — the exact duration depends on how that specific molecule is engineered.

It comes down to how resistant each molecule is to being broken down by DPP-4, the same enzyme that clears native GLP-1 in minutes. A more resistant molecule stays active longer between doses, which is why GLP-1 receptor agonists come in both short-acting (daily) and long-acting (weekly) formulations.

Related articles

References

  1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
  2. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14(8):675-688.